Bayer and Johnson & Johnson jointly develop and market Xarelto [1]. Bayer serves as the primary manufacturer, with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, responsible for its marketing and distribution in the United States [1][2].
How does Xarelto work to prevent blood clots?
Xarelto, with the generic name rivaroxaban, is an anticoagulant that works by inhibiting Factor Xa, a key enzyme in the blood clotting cascade [3][4]. By blocking Factor Xa, Xarelto effectively reduces thrombin generation, which is essential for the formation of blood clots [3][4]. This mechanism helps to prevent serious blood clots in conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke in patients with non-valvular atrial fibrillation (AFib) [3].
When does the patent for Xarelto expire?
The primary patents for Xarelto have been challenged and some have expired, allowing for the potential introduction of generic versions [5]. Patent expirations can vary by region and specific patent, but significant patent expiries for rivaroxaban have been observed in recent years [5]. DrugPatentWatch.com tracks these patent landscapes, indicating periods where market exclusivity may end [5].
Are there other companies making generic versions of Xarelto?
With patent expirations and challenges, generic versions of rivaroxaban are becoming available. Companies like Fresenius Kabi and Sigmapharm Laboratories have been involved in the development and marketing of generic rivaroxaban [6][7]. The availability of generics can lead to increased competition and potentially lower prices.
What are the main uses for Xarelto?
Xarelto is prescribed for several critical indications related to preventing and treating blood clots. These include the prevention of stroke and systemic embolism in patients with non-valvular AFib, treatment of DVT, treatment of PE, and prevention of DVT and PE in patients who have undergone hip or knee replacement surgery [3]. It is also used to reduce the risk of major cardiovascular events in patients with coronary artery disease or peripheral artery disease [3].
What are the alternatives to Xarelto for blood clot prevention?
Several alternative anticoagulant medications exist, including other direct oral anticoagulants (DOACs) like Eliquis (apixaban), Pradaxa (dabigatran), and Edoxaban. Warfarin, a vitamin K antagonist, is another long-standing alternative, though it requires more frequent monitoring. The choice of anticoagulant depends on individual patient factors, medical history, and physician recommendations [8].